Published in final edited form as:

J Org Chem. 2008 July 4; 73(13): 4874–4881. doi:10.1021/jo800444y.

Synthesis of 5-Fluoroalkylated Pyrimidine Nucleosides *via* Negishi Cross-Coupling

Ann-Marie Chacko[†], Wenchao Qu[‡], and Hank F. Kung^{†,‡}

Hank F. Kung: kunghf@sunmac.spect.upenn.edu

[†]Department of Pharmacology, University of Pennsylvania, 3700 Market Street, Suite 305, Philadelphia, PA 19104, USA

[‡]Department of Radiology, University of Pennsylvania, 3700 Market Street, Suite 305, Philadelphia, PA 19104, USA

Abstract

5-fluoroalkylated pyrimidine nucleosides (**1**) have potential as therapeutic agents and molecular imaging agents targeting HSV1-*tk* suicide gene therapy. Thus, straightforward preparation of 5-fluoroalkylated nucleoside derivatives has been developed. Reported herein are the first examples of Pd-catalyzed Negishi cross-coupling of 3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-iodo-2'-deoxyuridine (**2a**) and 3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-iodo-2'-deoxy-2'-fluoroarabinouridine (**2b**) with unactivated Csp³ fluoroalkylzinc bromides. This paper demonstrates the first synthesis of six 5-fluoroalkyl-2'-deoxy pyrimidine nucleoside derivatives with three to five methylene-chain lengths (**5**). Furthermore, this methodology has been extended to create a series of thirteen 5-alkyl substituted nucleosides, including the target nucleosides **5** and 5-silyloxypropyl and 5-cyanobutyl derivatives.

Introduction

The convenient access to functionalized nucleosides has been driven by the demonstrated pharmacological activity of nucleoside analogues against a broad spectrum of biological targets.ⁱ In particular, several 5-substituted pyrimidine nucleosides show potent and selective anti-herpes activity.ⁱⁱ The selectivity of pyrimidine nucleosides for herpes-infected cells is due to the specific phosphorylation of nucleoside substrates by the virus-encoded thymidine kinase, HSV1-TK. Parallel to this paradigm, the HSV1-*tk* gene expressing the HSV1-TK proteinⁱⁱⁱ has been exploited an important strategy for the suicide gene therapy of cancer where transduced cancer cells expressing the viral protein are made more sensitive to nucleoside therapy.^{iv} Our research interest is in the development of ¹⁸F-radiolabeled^v 5-fluoroalkylated pyrimidine nucleosides ([¹⁸F]**1a–f**) (Figure 1) that can be used as probes for the non-invasive *in vivo* molecular imaging of HSV1-TK in genetically transduced cells to correlate with the effectiveness of gene therapy and to monitor chemotherapy.^{vi} These

Correspondence to: Hank F. Kung, kunghf@sunmac.spect.upenn.edu.

Supporting Information Available: General experimental procedures and characterization data for compounds **2a,b**, **3**, **4**, **5a** (with **5h**), **6**, and **7a**, HPLC chromatogram of typical coupling reaction, and NMR spectra (¹H and ¹³C) for compounds **2a,b**, **3**, **4**, **6**, **7a**, **5a'–m**, and **1c,d**. This material is available free of charge *via* the Internet at <http://pubs.acs.org>.

radioactive probes have been designed to allow for: (i) rapid and efficient preparation of [^{18}F]**1a–f** by convenient radiochemistry, (ii) assessment of the stability effect of the 2'-hydrogen vs. 2'-fluorine on the glycosidic bond *in vivo*, and (iii) selective phosphorylation by HSV1-TK and thus accumulation in HSV1-TK expressing cells. However, in order to validate the preparation of the ^{18}F -labeled nucleosides, a practical synthesis of the nonradioactive molecules **1a–f** first needs to be developed for testing the binding affinity to HSV1-TK. This research effort is also motivated by the potential antiviral and antitumor activity of these novel nucleosides.

Several synthetic approaches allow access to 5-fluoroalkyl pyrimidine nucleosides. The classical approach calls for the preparation of 5-substituted uracils from corresponding 5-alkylbarbituric acids^{vii} followed by glycosylation of the uracils with reactive pentose derivatives.^{viii} This methodology suffers from typically low yields due to multiple steps, and extensive purification due to insufficient anomeric selectivity during the coupling step. A straightforward method to C-5 modified pyrimidine nucleosides is the palladium-catalyzed cross-coupling reactions of 5-iodouridine derivatives with terminal alkynes,^{ix} or by means of an organometallic reagent of mercury,^x stannane,^{xi} boron,^{xic} or zinc,^{xii} for example. During our studies on the synthesis of HSV1-TK molecular imaging probes with a pyrimidine core, 3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-iodo-2'-deoxyuridine (**2a**) and 3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-iodo-2'-deoxy-2'-fluoroarabinouridine (**2b**), were found to be the key synthetic intermediates in metal-catalyzed cross-coupling reactions. These intermediates were readily accessible from 5-iodo-2'-deoxyuridine,^{xiii,xiv} which is commercially available or from 5-iodo-2'-deoxy-2'-fluoroarabinouridine^{xv} obtained following a modified literature procedure.^{xvi}

Our initial approach to 5-fluoroalkyl nucleosides was to follow the palladium-catalyzed Sonogashira coupling route that has been reported by several groups.^{ix,xvii} One example is shown in Scheme 1 for the preparation of the tribenzoyl-protected 5-fluoropropyl-2'-deoxyuridine **5a**. The propargylated derivative **3** was obtained in very good yield, and the critical fluorination step, using DAST, afforded the fluoroalkyne **4** in moderate yields.^{xviii} However, this synthetic route was plagued by the significant defluorination observed during hydrogenation of **4** using Pd/C as the catalyst, resulting in inseparable mixture of products **5a** and **5h** (70:30 ratio, 89 %). Our observation mirrored that of a report that mono-fluoro-substituted olefins, such as fluoroethene and 3-fluoropropene, tend to eliminate fluorine during the course of coupling reactions with palladium.^{xix} First hydrogenating **3**, then fluorinating the saturated alcohol **6** with DAST, avoided the fluorine-elimination route, although the limitation to this approach was the very low yield of **5a** (< 14 %). TBAF was employed as an alternative fluorination method. However, reaction of mesylate **7a** with TBAF did not afford the fluorinated nucleoside **5a**. The disappointing results of this strategy, in particular, that of the hydrogenation step to **5a** and the fluorination step to **5a**, obviated the need to look at other strategies that allowed for direct coupling of the intact fluoroalkyl moiety.^{xx}

The palladium-catalyzed Negishi cross-coupling reactions of organohalides with organozinc reagents are another well-established and powerful method to forming carbon-carbon bonds.^{xxi} The ease in preparation,^{xxii} the high functional group tolerance, and reactivity of

organozinc reagents^{xxid} increases their synthetic utility. Contingent upon the preparation of the unactivated and saturated fluoroalkylzinc bromides from commercially available fluoroalkyl bromides, we chose the Negishi method to prepare our target nonradioactive nucleosides **1a–f**.

The first examples of Negishi coupling reactions employing 5-iodo-2'-deoxyuridine nucleosides described the Pd- or Ni- catalyzed Csp²–Csp² coupling of alkynyl-, indolyl- and thienylzinc reagents to 5-iodo-3',5'-di-*O*-bis-trimethylsilyl-protected 2'-deoxyuridine in 7–50 % yields.^{xii} A trifluoroisopropenylzincate with a Csp² center was also successfully coupled to 5-iodo-3',5'-di-*O*-benzoyl-protected 2'-deoxyuridine using Pd(PPh₃)₄ in 70 % yield.^{xxiii} Most recent reports indicate zincated nucleosides as an entry into 5-aryl-substituted uridines (Csp²–Csp² coupling).^{xxiv} However, to our knowledge, there exist no examples of Csp²–Csp³ cross-coupling reactions between 5-iodo-2'-deoxyuridine derivatives and unactivated and fully saturated alkylzincates. Reported herein are our efforts towards a convenient and efficient procedure for the preparation of 5-fluoroalkylated pyrimidine nucleosides **1a–f** by Negishi cross-coupling.

Results and Discussion

Our latest efforts to realize the **1a–f** by the Negishi cross-coupling approach focused on a rapid one-step preparation of tribenzoyl-protected 5-fluoroalkyl nucleosides **5a'–f** from the strategic intermediates **2a,b** (Scheme 2) and commercially available saturated fluoroalkyl bromides. Again, although compounds **5a'–f** themselves would be inactive against HSV1-TK, they represent the key precursors towards the final target nucleosides **1a–f**.

At the onset of our investigation, efforts were made to prepare the critical zinc reagent for subsequent coupling. Following an important report by Huo on the mild and facile preparation of alkylzinc bromides from alkyl bromides and common zinc powder with catalytic amounts of iodine,^{xxia,xxv} we observed high conversion of 4-fluorobutyl bromide to (4-fluorobutyl)zinc bromide in our model reaction.^{xxvi} With the zinc reagent in hand, experimentation began by monitoring the effect of catalyst on the Negishi cross-coupling reaction of **2a** with (4-fluorobutyl)zinc bromide, using the coupling conditions as described by Huo.^{xxia} Nine catalysts were selected for this analysis and the results of these experiments are summarized in Table 1. The Pd(PPh₃)₄ catalyst, which successfully coupled the activated isopropenylzinc reagent with the dibenzoyl-protected 5-iodo-2'-deoxyuridine,^{xxiii} as described previously, afforded trace amounts of the coupling product **5c** (entry 1, Table 1).^{xxvii} Employing a variety of catalytic systems shown to be effective in Negishi coupling reactions, including Cl₂Ni(PPh₃)₂,^{xxia} and Pd(dppf)Cl₂,^{xxviii} afforded the product in negligible yields (entries 2 and 3, Table 1). In addition, the Pd-N-heterocyclic carbene (NHC) catalyst, PEPPSI-IPr,^{xxix} did not yield any appreciable product (entry 4, Table 1).

Unlike the previous catalysts, experiments with Pd(P(*t*-Bu)₃)₂^{xxx} gave very encouraging results (entry 5, Table 1). We observed the coupling product **5c** in 47 % yield. The major by-product isolated is the de-iodinated nucleoside **8**, in which the iodide is replaced by hydrogen. The reason for this exchange has not been investigated. However, the major side

product **8** would most likely arise from competitive β -hydride elimination of the nucleoside-Pd(II)-alkyl intermediate as opposed to the desired reductive elimination of the same intermediate Pd(II) species to yield the coupled product. Subsequent reductive elimination of the nucleoside-Pd-H intermediate would form the de-iodinated product **8**. It may be suggested that acceleration of the reductive elimination step of the second intermediate Pd(II) species is critical to maximizing the yield of these reactions.

Bulky biphenylphosphine ligands are reported as improving Pd-catalyzed coupling yields by suppressing the tendency for destructive β -hydride elimination thus favoring reductive elimination.^{xxxii} Contrary to expectations, bulky Buchwald ligands such as S-Phos,^{xxivb,xxxii} cyclohexylJohnPhos (PCy₂-JohnPhos),^{xxxii} JohnPhos,^{xxxiii} and the Solvias ligand (R,S)-JosiPhos^{xxxiv} did not improve the coupling yields (entries 6–9, Table 1). Apparently, for most of the catalytic systems employed, oxidative addition was the rate-limiting step in the Negishi cross-coupling reactions as evidenced by the substantial recovery of starting material **2a**.

These initial experiments established that in our system, Pd(P(*t*-Bu)₃)₂ is the most effective catalyst in achieving cross-coupling between **2a** and (4-fluorobutyl)zinc bromide. Having obtained the coupling product we focused on further optimizing the reaction by increasing the consumption of the starting material **2a** and by increasing the ratio between product **5c** and de-iodinated nucleoside **8** (i.e. reductive elimination vs. β -hydride elimination).

Upon a more detailed investigation into the optimization of the coupling conditions several interesting observations were made (Table 2). A 1.6:1 ratio of Zn reagent/nucleoside resulted in a reasonably good yield within 1 h (entries 1–4, Table 2). Even more impressively, an increase in the stoichiometry increased the rate of reaction to afford the same product ratios in half the time (entries 5–12, Table 2) and lead to maximal consumption of the starting material. The reaction time is a critical factor due to the HPLC detection of degradation products within 30 min of initiation of the reaction, which typically increased in relative intensity with longer reaction times. The data also suggested that the stability of the nucleoside in the reaction mixture was dependent on the Zn reagent/nucleoside ratio since degradation products were observed to a greater degree and isolated yields are lower with larger excesses of Zn reagent (entries 8, 12, and 13, Table 2). Regardless of the stoichiometry of reagents used, no more than 53 % of **5c** could be obtained in any of the coupling conditions investigated. Furthermore, the ratio of **5c** to **8** remained more or less constant, and there typically remained trace amounts of starting material **2a**. As such, based on isolated yields, entry 6 of Table 2 was chosen as the optimized Negishi cross-coupling condition.

Preparation of a Series of 5-Alkylated Nucleoside Derivatives

To demonstrate the utility and versatility of the optimized Negishi cross-coupling methodology, a series of 5-alkylated nucleosides derivatives, including our desired 5-fluoroalkyl nucleosides **5a'–f**, was prepared using a variety of alkylzinc reagents (Table 3). A variety of zinc reagents could be successfully coupled to the nucleosides **2a** or **2b** in appreciable yields. As expected, (4-fluorobutyl)zinc and (5-fluoropentyl)zinc bromides were

prepared in high yields (> 0.74 M) following the Huo method,^{xxiia} and subsequent coupling to **2a** or **2b** afforded the coupling products **5c–5f** in moderate yields (entries 4–7, Table 3). Interestingly, attempts at preparing the short-chained (3-fluoropropyl)zinc and (2-fluoroethyl)zinc bromides were unsuccessful (entries 1 and 8, Table 3). Using the more reactive 3-iodo-1-fluoropropane, we obtained the corresponding alkylzinc iodide reagent, albeit in lower yields as compared to the longer chain fluoroalkylzinc bromides.^{xxxv} Cross-coupling of the zinc reagent with **2a,b** afforded the coupled products **5a',b** after 24 h in very low yield (< 8 %) (entry 2 and 3, Table 3). In an analogous fashion, short chain alkanes were coupled to **2a** through an alkylzinc iodide intermediate (entries 9–11, Table 3). The nucleosides **5g–i** were generated in low yields (15–23 %) but it is important to note that they were obtained in yields higher than those observed with the short chain fluoroalkyl zincates. This result suggests that the fluorine moiety confers instability to the desired zinc intermediate thus leading to low (or no) yields of the zinc reagent and very low isolated yields of the coupling product.

The efficiency of Negishi cross-coupling reactions employing dialkylzinc derivatives^{xxxvi} led us to explore the effect of using the dialkylzinc in place of the alkylzinc halides for cross-coupling reactions with **2a**. When using the commercially available (*n*-Bu)₂Zn, the nucleoside derivative **5g'** was easily prepared, and in much greater yield (44 %) as compared to utilizing the monoalkylzinc reagent (15 %) (entry 12, Table 3). There was no difference in the isolated yield of **5i'** (23 %) when Et₂Zn vs. EtZnI was used (entry 13, Table 3). Of note, however, is that either zinc reagent successfully generated nucleoside **5i/5i'**, which upon deprotection of the benzoyl groups would afford the potent antiherpes agent 5-ethyl-2'-deoxyuridine (EDU, Edoxuridine, Aedurid®).^{ii,xxxvii} Employment of the Negishi cross-coupling approach using dialkylzinc reagents^{xxxviii} thus represents an alternative for synthesizing 5-alkylated nucleosides.

We extended our methodology to include other readily accessible functionalized alkylzinc reagents (entries 14–17, Table 3). Of particular interest was the successful coupling reaction employing (3-*tert*-butyldimethylsiloxypropyl)zinc bromide to afford **5m** (entry 15, Table 3). As elaborated in Scheme 3, silylated coupling products, *via* the OTBS moiety, offer an alternative route to rapidly obtaining mesylate precursors for subsequent ¹⁸F-radiolabeling to achieve our target HSV1-TK molecular imaging probes [¹⁸F]**1a–f**.^{xxxix} We have since prepared the series of six mesylate precursors **7a–f** that upon labeling with [¹⁸F]KF and Kryptofix (K[2,2,2]), followed by deprotection, have successfully afforded no-carrier added [¹⁸F]**1a–f** in good yields and in short preparation times. Details of the radiolabeling studies and biological characterizations of [¹⁸F]**1a–f** will be published elsewhere.

Deprotection

Access to the bioactive nucleosides targeting HSV1-TK was exemplified using the above-prepared nucleoside derivatives **5c** and **5d**. The 3-*N*-benzoyl and 3',5'-di-*O*-benzoyl-protecting groups were hydrolyzed by treatment of **5c,d** with a standard solution of sodium methoxide in anhydrous methanol for 15 min under reflux. The corresponding unprotected nucleosides 5-fluorobutyl-2'-deoxyuridine (**1c**) and 5-fluorobutyl-2'-deoxy-2'-fluoroarabinouridine (**1d**) were obtained in very high yields (> 95 %) demonstrating that

benzoyl removal was compatible with the presence of the 5-fluoroalkyl moieties. This procedure allowed for the rapid and efficient two-step preparation of the bioactive compounds **1c** from **2a** and **1d** from **2b** in 52 % and 41 % overall yields.

Conclusions

Our studies demonstrate the first Pd(P(*t*-Bu)₃)₂-catalyzed cross-coupling reactions between fully protected 5-iodo-2'-deoxyuridine nucleosides and unactivated alkylzinc reagents. Furthermore, this methodology represents a significant improvement over conventional syntheses to 5-alkyl substituted pyrimidine nucleosides that typically involve multiple steps affording products in lower overall chemical yields.^{vii,viii} As such, our approach provides easier access to biologically important 5-alkyl substituted pyrimidine nucleosides, including our new series of 5-fluoroalkylated pyrimidine nucleosides. We are currently expanding the scope of this reaction to include more elaborate zinc reagents.

Experimental Section

Typical Procedure for Cross-Coupling of **2a** or **2b** with Organozinc Species

In a flame-dried 5-mL two-neck flask equipped with a stir bar was added **2a** (0.08 mmol) or **2b** (0.08 mmol), Pd(P(*t*-Bu)₃)₂ (1.9 mg, 0.004 mmol) and anhyd DMA (1 mL) under argon. To the reaction mixture, alkylzinc reagent^{xxiia} (0.6–0.9M solution in DMA, 0.23 mmol) or dialkylzinc reagent (230 μ L of 1 M in heptane, 0.23 mmol) was added dropwise and the reaction stirred at room temperature for 30 min. The reaction was monitored by HPLC (Method A) and judged to be complete. The reaction mixture was quenched with saturated NH₄Cl (5 mL) and extracted with EtOAc (3 $\times$ 5 mL). The combined organic extracts were washed with brine, dried over MgSO₄, filtered and concentrated. The crude product mixture was purified by silica gel preparative thin layer chromatography (PTLC) using of 20 % to 30 % EtOAc in hexanes.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(3-fluoropropyl)-2'-deoxyuridine (**5a'**)

2a (50 mg, 0.08 mmol) and Pd(P(*t*-Bu)₃)₂ (1.9 mg, 0.004 mmol) with (3-fluoropropyl)zinc iodide (375 μ L of 0.6 M solution in DMA, 0.23 mmol) afforded 4 mg of **5a'**, 8 % yield. ¹H NMR (200 MHz, CDCl₃) δ 8.10–7.90 (m, 6H), 7.70–7.42 (m, 9H+1H), 6.45 (dd, 1H, J_1 = 5.5 Hz and J_2 = 8.4 Hz), 5.70–5.66 (m, 1H), 4.79 (dd, 1H, J_1 = 12.3 Hz and J_2 = 25.1 Hz), 4.77 (dd, 1H, J_1 = 12.2 and J_2 = 26.0 Hz), 4.58 (m, 1H), 4.33 (dt, 2H, J_1 = 5.7 Hz and J_2 = 47.3 Hz), 2.78 (dd, 1H, J_1 = 5.2 Hz and J_2 = 14.1 Hz), 2.47–2.32 (m, 1H), 2.18–2.09 (m, 2H), 1.69–1.39 (m, 2H). ¹³C NMR (50 MHz, CDCl₃) δ 168.8, 166.2, 162.3, 149.4, 135.3, 135.0, 135.96, 131.7, 130.6, 130.0, 129.7, 129.5, 129.4, 129.2, 129.1, 128.8, 114.9, 85.6, 83.3 (d, J = 164.7 Hz), 83.2, 75.1, 64.5, 38.4, 29.2 (d, J = 19.9 Hz), 23.8 (d, J = 5.6 Hz). HRMS calcd for C₃₃H₂₉FN₂O₈Na ([M+Na]⁺) 623.1806, found 623.1830. HPLC A: t_R = 10.5 min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(3-fluoropropyl)-2'-deoxy-2'-fluoroarabinouridine (**5b**)

2b (51 mg, 0.08 mmol) and Pd(P(*t*-Bu)₃)₂ (1.9 mg, 0.004 mmol) with (3-fluoropropyl)zinc iodide (375 μ L of 0.6 M solution in DMA, 0.23 mmol) afforded 3 mg of **5b**, 5 % yield. ¹H

NMR (200 MHz, CD₃CN) δ 8.12–7.94 (m, 6H), 7.79–7.43 (m, 9H+1H), 6.31 (dd, 1H, J_1 = 3.2 Hz and J_2 = 20.7 Hz), 5.69 (ddd, 1H, J_1 = 1.0 Hz, J_2 = 3.6 Hz and J_3 = 19.0 Hz), 5.44 (ddd, 1H, J_1 = 1.0 Hz, J_2 = 3.3 Hz and J_3 = 50.2 Hz), 4.79 (dd, 1H, J_1 = 12.1 Hz and J_2 = 24.6 Hz), 4.77 (dd, 1H, J_1 = 12.1 Hz and J_2 = 25.8 Hz), 4.65–4.59 (m, 1H), 4.37 (dt, 2H, J_1 = 5.9 Hz and J_2 = 47.4 Hz), 2.34–2.27 (m, 2H), 1.76–1.70 (m, 2H). ¹³C NMR (50 MHz, CD₃CN) δ 170.4, 167.1, 166.4, 163.5, 150.1, 138.4, 138.3, 136.6, 135.0, 134.6, 132.6, 131.4, 130.9, 130.5, 130.1, 129.8, 114.2, 94.4 (d, J = 189.8 Hz), 85.7 (d, J = 16.5 Hz), 84.4 (d, J = 161.6 Hz), 81.5, 77.9 (d, J = 30.3 Hz), 64.3, 30.1 (d, J = 19.5 Hz), 23.8 (d, J = 5.7 Hz). HRMS calcd for C₃₃H₂₉F₂N₂O₈ ([M+H]⁺) 619.1892, found 619.1896. HRMS calcd for C₃₃H₂₈F₂N₂O₈ Na ([M+Na]⁺) 641.1711, found 641.1710. HPLC A: t_R = 12.1 min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(4-fluorobutyl)-2'-deoxyuridine (5c)

2a (50 mg, 0.08 mmol) and Pd(P(*t*-Bu)₃)₂ (1.9 mg, 0.004 mmol) with (4-fluorobutyl)zinc bromide (250 μ L of 0.9 M solution in DMA, 0.23 mmol) afforded cross-coupling product **5c** as a white solid (24 mg, 53 % yield). ¹H NMR (200 MHz, CDCl₃) δ 8.10–7.89 (m, 6H), 7.70–7.39 (m, 9H+1H), 6.46 (dd, 1H, J_1 = 5.4 Hz and J_2 = 8.8 Hz), 5.68 (dt, 1H, J_1 = 1.5 Hz and J_2 = 6.5 Hz), 4.78 (dd, 1H, J_1 = 12.2 Hz and J_2 = 28.8 Hz), 4.77 (dd, 1H, J_1 = 12.2 Hz and J_2 = 29.5 Hz), 4.59–4.55 (m, 1H), 4.35 (dt, 2H, J_1 = 5.7 Hz and J_2 = 47.3 Hz), 2.78 (ddd, 1H, J_1 = 1.3 Hz and J_2 = 5.4 Hz and J_3 = 14.2 Hz), 2.47–2.32 (m, 1H), 2.22–2.12 (m, 2H), 1.69–1.39 (m, 4H). ¹³C NMR (50 MHz, CDCl₃) δ 168.9, 166.2, 162.4, 149.4, 135.3, 134.6, 134.0, 131.8, 130.6, 130.0, 129.7, 129.5, 129.4, 129.2, 129.1, 128.8, 128.3, 115.7, 85.6, 83.8 (d, J = 163.9 Hz), 83.1, 75.2, 64.5, 38.3, 30.1 (d, J = 19.7 Hz), 26.9, 24.6 (d, J = 5.1 Hz). HRMS calcd for C₃₄H₃₂FN₂O₈ ([M+H]⁺) 615.2143, found 615.2148. HPLC A: t_R = 11.6 min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(4-fluorobutyl)-2'-deoxy-2'-fluoroarabinouridine (5d)

2b (51 mg, 0.08 mmol) and Pd(P(*t*-Bu)₃)₂ (1.9 mg, 0.004 mmol) with (4-fluorobutyl)zinc bromide (281 μ L of 0.8 M solution in DMA, 0.23 mmol) afforded 20 mg of **5d**, 43 % yield. ¹H NMR (200 MHz, CD₃CN) δ 8.13–7.94 (m, 6H), 7.79–7.49 (m, 9H+1H), 6.32 (dd, 1H, J_1 = 3.1 Hz and J_2 = 20.8 Hz), 5.70 (dd, 1H, J_1 = 3.2 Hz and J_2 = 18.8 Hz), 5.45 (dd, 1H, J_1 = 2.4 Hz and J_2 = 50.2 Hz), 4.80 (dd, 1H, J_1 = 12.1 Hz and J_2 = 29.2 Hz), 4.78 (dd, 1H, J_1 = 12.1 Hz and J_2 = 30.6 Hz), 4.65–4.62 (m, 1H), 4.36 (dt, 2H, J_1 = 6.0 Hz and J_2 = 47.4 Hz), 2.25–2.18 (m, 2H), 1.64–1.46 (m, 4H). ¹³C NMR (50 MHz, CD₃CN) δ 170.4, 166.4, 163.5, 150.1, 138.2, 138.1, 136.5, 134.9, 134.6, 134.2, 132.6, 131.4, 130.8, 130.5, 130.1, 129.8, 129.6, 114.7, 94.4 (d, J = 189.7 Hz), 85.6 (d, J = 16.5 Hz), 84.9 (d, J = 160.9 Hz), 81.4, 77.8 (d, J = 30.3 Hz), 64.2, 30.5 (d, J = 19.5 Hz), 27.2, 25.1 (d, J = 5.4 Hz). HRMS calcd for C₃₄H₃₁F₂N₂O₈ ([M+H]⁺) 633.2048, found 633.2062. HPLC A: t_R = 13.2 min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(5-fluoropentyl)-2'-deoxyuridine (5e)

2a (50 mg, 0.08 mmol) and Pd(P(*t*-Bu)₃)₂ (1.9 mg, 0.004 mmol) with (5-fluoropentyl)zinc bromide (250 μ L of 0.9 M solution in DMA, 0.23 mmol) afforded 24 mg of **5e**, 50 % yield. ¹H NMR (200 MHz, CDCl₃) δ 8.10–7.90 (m, 6H), 7.66–7.43 (m, 9H), 7.36 (s, 1H), 6.47 (dd, 1H, J_1 = 5.4 Hz and J_2 = 8.8 Hz), 5.70–5.67 (m, 1H), 4.78 (dd, 1H, J_1 = 12.2 Hz

and $J_2 = 28.7$ Hz), 4.76 (dd, 1H, $J_1 = 12.2$ Hz and $J_2 = 29.5$ Hz), 4.5 (m, 1H), 4.34 (dt, 2H, $J_1 = 5.7$ Hz and $J_2 = 47.2$ Hz), 2.78 (dd, 1H, $J_1 = 5.3$ Hz and $J_2 = 14.2$ Hz), 2.40 (ddd, 1H, $J_1 = 6.3$ Hz and $J_2 = 8.5$ Hz and $J_3 = 14.5$ Hz), 2.18–1.97 (m, 2H), 1.72–1.27 (m, 6H). ^{13}C NMR (50 MHz, CDCl_3) δ 168.9, 166.2, 162.4, 149.4, 135.3, 134.4, 134.0, 131.8, 130.6, 130.0, 129.7, 129.5, 129.4, 129.2, 129.1, 128.8, 116.0, 85.5, 84.0 (d, $J = 163.5$ Hz), 83.1, 75.2, 64.6, 38.3, 30.2 (d, $J = 19.5$ Hz), 28.3, 27.2, 25.0 (d, $J = 5.1$ Hz). HRMS calcd for $\text{C}_{35}\text{H}_{34}\text{FN}_2\text{O}_8$ ($[\text{M}+\text{H}]^+$) 629.2299, found 629.2298. HPLC A: $t_R = 13.7$ min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(5-fluoropentyl)-2'-deoxy-2'-fluoroarabinouridine (5f)

2b (51 mg, 0.08 mmol) and $\text{Pd}(\text{P}(t\text{-Bu})_3)_2$ (1.9 mg, 0.004 mmol) with (5-fluoropentyl)zinc bromide (268 μL of 0.84 M solution in DMA, 0.23 mmol) afforded 26 mg of **5f**, 53 % yield. ^1H NMR (200 MHz, CD_3CN) δ 8.13–7.95 (m, 6H), 7.75–7.50 (m, 9H+1H), 6.33 (dd, 1H, $J_1 = 3.0$ Hz and $J_2 = 20.8$ Hz), 5.70 (dd, 1H, $J_1 = 3.0$ Hz and $J_2 = 18.9$ Hz), 5.46 (dd, 1H, $J_1 = 2.6$ Hz and $J_2 = 50.2$ Hz), 4.80 (dd, 1H, $J_1 = 12.1$ Hz and $J_2 = 31.0$ Hz), 4.78 (dd, 1H, $J_1 = 12.1$ Hz and $J_2 = 32.5$ Hz), 4.65–4.61 (m, 1H), 4.38 (dt, 2H, $J_1 = 6.0$ Hz and $J_2 = 47.5$ Hz), 2.21–2.14 (m, 2H), 1.71–1.28 (m, 6H). ^{13}C NMR (50 MHz, CD_3CN) δ 170.4, 166.4, 163.5, 150.1, 138.0, 137.9, 136.5, 134.9, 134.6, 134.2, 132.6, 131.3, 130.8, 130.6, 130.5, 130.1, 129.83, 129.81, 129.6, 115.0, 94.4 (d, $J = 189.8$ Hz), 85.6 (d, $J = 16.3$ Hz), 85.0 (d, $J = 160.8$ Hz), 81.5, 77.8 (d, $J = 30.3$ Hz), 64.2, 30.8 (d, $J = 19.3$ Hz), 28.9, 27.4, 25.4 (d, $J = 5.6$ Hz). HRMS calcd for $\text{C}_{35}\text{H}_{33}\text{F}_2\text{N}_2\text{O}_8$ ($[\text{M}+\text{H}]^+$) 647.2205, found 647.2202. HPLC A: $t_R = 15.2$ min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-butyl-2'-deoxyuridine (5g/5g')

2a (50 mg, 0.08 mmol) and $\text{Pd}(\text{P}(t\text{-Bu})_3)_2$ (1.9 mg, 0.004 mmol) with butylzinc iodide (281 μL of 0.8 M solution in DMA, 0.23 mmol) afforded 7 mg of **5g**, 15 % yield. Employing (*n*-Bu) $_2\text{Zn}$ (230 μL of 1 M in heptane, 0.23 mmol) afforded 20 mg of **5i'**, 44 % yield. ^1H NMR of **5g** (200 MHz, CDCl_3) δ 8.10–7.90 (m, 6H), 7.69–7.43 (m, 9H) 7.34 (s, 1H), 6.47 (dd, 1H, $J_1 = 5.5$ Hz and $J_2 = 8.7$ Hz), 5.70–5.67 (m, 1H), 4.78 (dd, 1H, $J_1 = 12.2$ Hz and $J_2 = 28.5$ Hz), 4.76 (dd, 1H, $J_1 = 12.2$ Hz and $J_2 = 29.3$ Hz), 4.57–4.56 (m, 1H), 2.77 (dd, 1H, $J_1 = 5.0$ Hz and $J_2 = 13.9$ Hz), 2.47–2.33 (m, 1H), 2.10–2.05 (m, 2H), 1.29–1.12 (m, 4H), 0.81 (t, 3H, $J = 7.0$ Hz). ^{13}C NMR of **5g** (50 MHz, CDCl_3) δ 169.0, 166.2, 162.4, 149.5, 135.2, 134.1, 134.0, 131.9, 130.6, 130.0, 129.8, 129.5, 129.4, 129.2, 129.0, 128.8, 116.5, 85.5, 83.1, 75.2, 64.6, 38.3, 30.8, 27.0, 22.5, 13.8. HRMS calcd for $\text{C}_{34}\text{H}_{32}\text{N}_2\text{O}_8\text{Na}$ ($[\text{M}+\text{Na}]^+$) 619.2056, found 619.2048. HPLC A: $t_R = 16.1$ min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-propyl-2'-deoxyuridine (5h')

2a (50 mg, 0.08 mmol) and $\text{Pd}(\text{P}(t\text{-Bu})_3)_2$ (1.9 mg, 0.004 mmol) with propylzinc iodide (281 μL of 0.8 M solution in DMA, 0.23 mmol) afforded 8 mg of **5h'**, 17 % yield. ^1H NMR (200 MHz, CDCl_3) δ 8.10–7.90 (m, 6H), 7.69–7.43 (m, 9H) 7.32 (s, 1H), 6.47 (dd, 1H, $J_1 = 5.5$ Hz and $J_2 = 8.7$ Hz), 5.71–5.68 (m, 1H), 4.78 (dd, 1H, $J_1 = 12.3$ Hz and $J_2 = 32.6$ Hz), 4.76 (dd, 1H, $J_1 = 12.3$ Hz and $J_2 = 33.4$ Hz), 4.57 (m, 1H), 2.77 (dd, 1H, $J_1 = 4.7$ Hz and $J_2 = 14.1$ Hz), 2.47–2.32 (m, 1H), 2.11–2.01 (m, 2H), 1.42–1.31 (m, 2H), 0.77 (t, 3H, $J = 7.2$ Hz). ^{13}C NMR (50 MHz, CDCl_3) δ 169.0, 166.2, 162.4, 149.5, 135.2, 134.2, 134.0, 131.9, 130.6, 130.0, 129.7, 129.5, 129.4, 129.2, 129.0, 128.8, 116.2, 85.4, 83.0, 75.2, 64.5, 38.3,

29.2, 21.8, 13.8. HRMS calcd for $C_{33}H_{30}N_2O_8Na$ ($[M+Na]^+$) 605.1900, found 605.1944. HPLC A: t_R = 13.5 min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-ethyl-2'-deoxyuridine (5i/5i')

2a (50 mg, 0.08 mmol) and $Pd(P(t-Bu)_3)_2$ (1.9 mg, 0.004 mmol) with ethylzinc iodide (312 μ L of 0.72 M solution in DMA, 0.23 mmol) afforded 10 mg of **5i**, 23 % yield. Employing Et_2Zn (230 μ L of 1 M in heptane, 0.23 mmol) afforded 10 mg of **5i'**, 23 % yield. 1H NMR of **5i** (200 MHz, $CDCl_3$) δ 8.09–7.91 (m, 6H), 7.69–7.43 (m, 9H), 7.33 (s, 1H), 6.47 (dd, 1H, J_1 = 5.4 Hz and J_2 = 8.6 Hz), 5.70–5.67 (m, 1H), 4.79 (dd, 1H, J_1 = 12.2 Hz and J_2 = 29.2 Hz), 4.77 (dd, 1H, J_1 = 12.2 Hz and J_2 = 29.9 Hz), 4.57–4.56 (m, 1H), 2.77 (dd, 1H, J_1 = 5.1 Hz and J_2 = 13.9 Hz), 2.40 (ddd, 1H, J_1 = 6.7 Hz and J_2 = 8.3 Hz and J_3 = 14.5 Hz), 2.15 (q, 2H, J = 7.3 Hz), 0.93 (t, 3H, J = 7.4 Hz). ^{13}C NMR of **5i** (50 MHz, $CDCl_3$) δ 169.0, 166.21, 166.16, 162.4, 149.5, 135.2, 134.0, 133.7, 131.9, 130.7, 130.4, 130.0, 129.8, 129.6, 129.4, 129.2, 129.0, 128.8, 128.7, 117.7, 85.5, 83.1, 75.2, 64.5, 38.3, 20.6, 13.0. HRMS calcd for $C_{32}H_{28}N_2O_8Na$ ($[M+Na]^+$) 591.1743, found 591.1739. HPLC A: t_R = 10.7 min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(5-acetoxypentyl)-2'-deoxyuridine (5j)

2a (50 mg, 0.08 mmol) and $Pd(P(t-Bu)_3)_2$ (1.9 mg, 0.004 mmol) with (5-acetoxypentyl)zinc bromide (281 μ L of 0.8 M solution in DMA, 0.23 mmol) afforded 17 mg of **5j**, 33 % yield. 1H NMR (200 MHz, $CDCl_3$) δ 8.41–7.90 (m, 6H), 7.69–7.43 (m, 9H), 7.36 (s, 1H), 6.46 (dd, 1H, J_1 = 5.4 Hz and J_2 = 8.6 Hz), 5.70–5.67 (m, 1H), 4.78 (dd, 1H, J_1 = 12.2 Hz and J_2 = 30.5 Hz), 4.76 (dd, 1H, J_1 = 12.2 Hz and J_2 = 31.4 Hz), 4.58–4.57 (m, 1H), 4.00 (t, 2H, J = 6.6 Hz), 2.78 (dd, 1H, J_1 = 5.2 Hz and J_2 = 14.1 Hz), 2.48–2.33 (m, 1H), 2.18–2.05 (m, 2H), 2.05 (s, 3H), 1.59–1.21 (m, 6H). ^{13}C NMR (50 MHz, $CDCl_3$) δ 171.3, 169.0, 166.2, 162.4, 149.4, 135.3, 134.4, 134.0, 131.8, 130.6, 130.0, 129.8, 129.6, 129.4, 129.2, 129.1, 128.8, 116.1, 85.6, 83.1, 75.2, 64.5, 38.3, 28.5, 27.2, 25.8, 21.2. HRMS calcd for $C_{37}H_{36}N_2O_{10}Na$ ($[M+Na]^+$) 691.2248, found 691.2268. HPLC A: t_R = 11.8 min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(4-ethoxy-4-oxobutyl)-2'-deoxyuridine (5k)

2a (50 mg, 0.08 mmol) and $Pd(P(t-Bu)_3)_2$ (1.9 mg, 0.004 mmol) with (4-ethoxy-4-oxobutyl)zinc bromide (300 μ L of 0.75 M solution in DMA, 0.23 mmol) afforded 19 mg of **5k**, 39 % yield. 1H NMR (200 MHz, $CDCl_3$) δ 8.09–7.91 (m, 6H), 7.65–7.41 (m, 9H+1H), 6.44 (dd, 1H, J_1 = 5.4 Hz and J_2 = 8.6 Hz), 5.69–5.66 (m, 1H), 4.78 (dd, 1H, J_1 = 12.2 Hz and J_2 = 22.4 Hz), 4.76 (dd, 1H, J_1 = 12.2 Hz and J_2 = 23.2 Hz), 4.57–4.56 (m, 1H), 4.1 (q, 2H, J = 7.1 Hz), 2.77 (dd, 1H, J_1 = 5.1 Hz and J_2 = 13.8 Hz), 2.42 (ddd, 1H, J_1 = 6.5 Hz and J_2 = 8.3 Hz and J_3 = 14.5 Hz), 2.21–2.14 (m, 2H), 2.17 (t, 2H, J = 7.2 Hz), 1.77–1.67 (m, 2H), 1.25 (t, 3H, J = 7.1 Hz). ^{13}C NMR (50 MHz, $CDCl_3$) δ 173.2, 168.9, 166.2, 162.3, 149.4, 135.2, 135.0, 133.9, 131.8, 130.7, 130.0, 129.8, 129.6, 129.4, 129.2, 129.0, 128.8, 128.3, 115.2, 85.7, 83.1, 75.2, 64.5, 38.3, 33.9, 26.8, 23.9, 14.5. HRMS calcd for $C_{36}H_{34}N_2O_{10}Na$ ($[M+Na]^+$) 677.2111, found 677.2093. HRMS calcd for $C_{36}H_{35}N_2O_{10}$ ($[M+H]^+$) 655.2292, found 655.2272. HPLC A: t_R = 11.4 min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(3-cyanopropyl)-2'-deoxyuridine (5l)

2a (50 mg, 0.08 mmol) and Pd(P(*t*-Bu)₃)₂ (1.9 mg, 0.004 mmol) with (3-cyanopropyl)zinc bromide (256 μ L of 0.88 M solution in DMA, 0.23 mmol) afforded 13 mg of **5l**, 29 % yield. ¹H NMR (200 MHz, CDCl₃) δ 8.11–7.91 (m, 6H), 7.67–7.43 (m, 9H + 1H), 6.43 (dd, 1H, J_1 = 5.4 Hz and J_2 = 8.5 Hz), 5.69–5.66 (m, 1H), 4.80 (dd, 1H, J_1 = 12.2 Hz and J_2 = 27.3 Hz), 4.79 (dd, 1H, J_1 = 12.2 Hz and J_2 = 28.6 Hz), 4.59 (m, 1H), 2.81 (dd, 1H, J_1 = 5.3 Hz and J_2 = 14.2 Hz), 2.47–2.36 (m, 1H), 2.33–2.08 (m, 4H), 1.79–1.69 (m, 2H). ¹³C NMR (50 MHz, CDCl₃) δ 168.7, 166.2, 162.3, 149.3, 135.8, 135.4, 134.1, 134.0, 131.7, 130.7, 130.0, 129.8, 129.6, 129.5, 129.2, 128.9, 119.4, 113.6, 85.9, 83.4, 75.2, 53.6, 38.5, 26.9, 24.2, 16.9. HRMS calcd for C₃₄H₂₉N₃O₈Na ([M+Na]⁺) 630.1852, found 630.1874. HPLC A: t_R = 8.5 min.

3-*N*-benzoyl-3',5'-di-*O*-benzoyl-5-(3-*tert*-butyldimethylsilyloxypropyl)-2'-deoxyuridine (5m)

2a (50 mg, 0.08 mmol) and Pd(P(*t*-Bu)₃)₂ (1.9 mg, 0.004 mmol) with (3-*tert*-butyldimethylsilyloxypropyl)zinc bromide (321 μ L of 0.7 M solution in DMA, 0.23 mmol) afforded 25 mg of **5m**, 47 % yield. ¹H NMR (200 MHz, CD₃CN) δ 8.09–7.90 (m, 6H), 7.69–7.42 (m, 9H), 7.40 (s, 1H), 6.43 (dd, 1H, J_1 = 5.4 Hz and J_2 = 8.7 Hz), 5.67–5.64 (m, 1H), 4.77 (dd, 1H, J_1 = 12.2 Hz and J_2 = 14.4 Hz), 4.75 (dd, 1H, J_1 = 12.2 Hz and J_2 = 14.6 Hz), 4.59–4.55 (m, 1H), 3.51 (t, 2H, J = 6.2 Hz), 2.77 (ddd, 1H, J_1 = 1.4 Hz and J_2 = 5.4 Hz and J_3 = 14.2 Hz), 2.40 (ddd, 1H, J_1 = 6.6 Hz and J_2 = 8.6 Hz and J_3 = 14.4 Hz), 2.30–2.19 (m, 2H), 1.66–1.52 (m, 2H), 0.88 (s, 9H), 0.03 (s, 6H). ¹³C NMR (50 MHz, CDCl₃) δ 169.0, 166.2, 162.4, 149.4, 135.2, 134.4, 134.0, 133.9, 131.9, 130.7, 130.0, 129.8, 129.6, 129.4, 129.2, 129.0, 128.8, 115.9, 85.8, 83.1, 75.2, 64.5, 62.6, 38.3, 31.5, 26.2, 24.1, 18.5, -5.1. HRMS calcd for C₃₉H₄₄N₂O₉SiNa ([M+Na]⁺) 735.2174, found 735.2688. HRMS calcd for C₃₉H₄₅N₂O₉Si ([M+H]⁺) 713.2894, found 713.2881. HPLC A: t_R = 15.1 min.

Typical Procedure for Deprotection of Tribenzoyl-Protected Nucleosides

In vial equipped with a stir bar was added tribenzoylprotected nucleosides. Dry 0.5 N NaOMe in MeOH solution (3 mL) was added dropwise. Reaction vial was sealed and then stirred at 80°C for 15 min. Reaction judged to be complete by HPLC (MeOH/H₂O (30/70)). After cooling to room temperature, reaction was quenched with 1N HCl (1.5 mL) and the solvent removed *in vacuo*. The crude product residue was purified by silica gel PTLC using 10 % MeOH in dichloromethane.

5-(4-fluorobutyl)-2'-deoxyuridine (1c)

The deprotection procedure described above, using **5c** (23.4 mg, 0.04 mmol) afforded 11.5 mg of **1c**, 99 % yield. ¹H NMR (200 MHz, CD₃OD) δ 8.06 (s, 1H), 6.49 (t, 1H, J_1 = 6.7 Hz), 4.64 (dt, 2H, J_1 = 5.6 Hz and J_2 = 47.6 Hz), 4.64–4.57 (m, 1H), 4.12 (t, 1H, J_1 = 3.1 Hz), 3.98 (dd, 1H, J_1 = 12.1 Hz and J_2 = 16.8 Hz), 3.96 (dd, 1H, J_1 = 12.1 Hz and J_2 = 17.3 Hz), 2.59–2.37 (m, 2H+2H), 2.00–1.81 (m, 4H). ¹³C NMR (50 MHz, CD₃OD) δ 166.1, 152.4, 138.6, 115.6, 89.1, 86.6, 84.8 (d, J = 162.8 Hz), 72.4, 62.9, 41.5, 31.2 (d, J = 19.6 Hz), 27.5, 25.6 (d, J = 5.1 Hz). HRMS calcd for C₁₃H₂₀FN₂O₅ ([M+H]⁺) 303.1356, found 303.1349. HPLC B: t_R = 7.6 min.

5-(4-fluorobutyl)-2'-deoxy-2'-fluoroarabinouridine (**1d**)

The deprotection procedure above, using **5d** (12.7 mg, 0.021 mmol) afforded 6.1 mg of **1d**, 95 % yield. ¹H NMR (200 MHz, CD₃CN with D₂O) δ 7.53 (s, 1H), 6.13 (dd, 1H, $J_1 = 4.1$ Hz and $J_2 = 16.4$ Hz), 5.02 (dt, 2H, $J_1 = 3.9$ Hz and $J_2 = 52.2$ Hz), 4.43 (dt, 2H, $J_1 = 5.9$ Hz and $J_2 = 47.3$ Hz), 4.24–4.20 (m, 1H), 3.90–3.70 (m, 1H+2H), 2.32–2.25 (m, 2H), 1.78–1.45 (m, 4H). ¹³C NMR (50 MHz, CD₃CN with D₂O) δ 164.2, 151.2, 138.0 (d, $J = 3.0$ Hz), 114.2, 96.8 (d, $J = 190.4$ Hz), 85.0 (d, $J = 160.7$ Hz), 84.5 (d, $J = 4.6$ Hz), 84.0 (d, $J = 16.6$ Hz), 74.4 (d, $J = 24.5$ Hz), 61.5, 30.6 (d, $J = 19.4$ Hz), 27.1, 25.0 (d, $J = 5.4$ Hz). HRMS calcd for C₁₃H₁₉F₂N₂O₅ [(M+H)⁺] 321.1262, found 321.1253. HPLC B: $t_R = 10.9$ min.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by NIH Grant R21EB005242 (H.F.K). Dr. K. Ploessl is thanked for carrying out HRMS.

References and Footnotes

- (i). For examples see: Galmarini C, Mackey J, Dumontet C. *Lancet Oncol.* 2002; 3:415–24. [PubMed: 12142171] Balzarini J, McGuigan C. *J Antimicrob Chemother.* 2002; 50:5–9. [PubMed: 12096000] Gumina G, Song G, Chu C. *FEMS Microbiol Lett.* 2001; 202:9–15. [PubMed: 11506901] Jordheim LP, Galmarini CM, Dumontet C. *Recent Patents Anticancer Drug Discov.* 2006; 1:163–70.
- (ii). Kumar R. *Curr Med Chem.* 2004; 11:2749–66. and all references therein. [PubMed: 15544474]
- (iii). Note that HSV1-*tk* denotes the gene and HSV1-TK denotes the protein (i.e. the gene product)
- (iv). (a) Furman PA, McGuirt PV, Keller PM, Fyfe JA, Elion GB. *Virology.* 1980; 102:420–30. [PubMed: 6245517] (b) Freeman SM. *Adv Exp Med Biol.* 2000; 465:411–22. [PubMed: 10810645] (d) Mullen CA. *Pharmacol Ther.* 1994; 63:199–207. [PubMed: 7809180] (c) Wei MX, Bougnoux P, Sacre-Salem B, Peyrat MB, Lhuillery C, Salzmann JL, Klatzmann D. *Cancer Res.* 1998; 58:3529–32. [PubMed: 9721854]
- (v). CAUTION: ¹⁸F is a radioactive material (radioactive half-life ($t_{1/2}$) = 110 min, β^+ emission = 511 keV) and should only be used by trained research personnel with the appropriate safety precautions.
- (vi). For reviews on molecular imaging of HSV1-tk gene expression: Serganova I, Blasberg R. *Nucl Med Biol.* 2005; 32:763–80. [PubMed: 16243653] Blasberg R. *Eur J Cancer.* 2002; 38:2137–46. [PubMed: 12387839] Penuelas I, Boan J, Marti-Climent JM, Sangro B, Mazzolini G, Prieto J, Richter JA. *Mol Imaging Biol.* 2004; 6:225–38. [PubMed: 15262238]
- (vii). (a) Griengl H, Wanek E, Schwarz W, Streicher W, Rosenwirth B, Clercq ED. *J Med Chem.* 1987; 30:1199–204. [PubMed: 3037079] (b) Su TL, Watanabe KA, Schinazi RF, Fox JJ. *J Med Chem.* 1986; 29:151–4. [PubMed: 3001306] (c) Volwiler EH. *J Am Chem Soc.* 1925; 47:2236–2240.
- (viii). (a) Hoffer M. *Chem Ber.* 1960; 93:2777–2781. (b) Reichman U, Watanabe KA, Fox JJ. *Carbohydr Res.* 1975; 42:233–240. [PubMed: 1139559] (c) Tann CH, Brodfuehrer PR, Brundidge SP, Sapino C Jr, Howell HG. *J Org Chem.* 1985; 50:3644–7.
- (ix). (a) Robins MJ, Barr PJ. *Tetrahedron Lett.* 1981; 22:421–424. (b) Robins MJ, Barr PJ. *J Org Chem.* 1983; 48:1854–1862.
- (x). Bergstrom DE. *Nucleosides Nucleotides.* 1982; 1:1–34. and all references therein.
- (xi). (a) Crisp GT. *Synth Commun.* 1989; 19:2117–23. (b) Crisp GT, Macolino V. *Synth Commun.* 1990; 20:413–22. (c) Crisp GT, Flynn BL. *Tetrahedron Lett.* 1990; 31:1347–50. (d) Herdewijn P,

- Kerremans L, Wigerinck P, Vandendriessche F, Van Aerschot A. *Tetrahedron Lett.* 1991; 32:4397–4400.(e) Farina V, Hauck SI. *Synlett.* 1991:157–9.
- (xii). (a) Vincent P, Beaucourt JP, Pichat L, Balzarini J, De Clercq E. *Nucleosides Nucleotides.* 1985; 4:429–45.(b) Vincent P, Beaucourt JP, Pichat L. *Tetrahedron Lett.* 1984; 25:201–2.(c) Vincent P, Beaucourt JP, Pichat L. *Tetrahedron Lett.* 1981; 22:945–7.
- (xiii). (a) Jin F, Xu Y. *J Fluorine Chem.* 1994; 67:1–4.(b) Matsushashi H, Hatanaka Y, Kuroboshi M, Hiyama T. *Heterocycles.* 1996; 42:375–84.
- (xiv). Maguire AR, Hladezuk I, Ford A. *Carbohydr Res.* 2002; 337:369–372. [PubMed: 11841817]
- (xv). Fulcrand-el Kattan G, Goudgaon NM, Ilksoy N, Huang JT, Watanabe KA, Sommadossi JP, Schinazi RF. *J Med Chem.* 1994; 37:2583–8. [PubMed: 8057301]
- (xvi). (a) Alauddin MM, Conti PS, Fissekis JD, Watanabe KA. *Synth Commun.* 2002; 32:1757–1764. (b) Hubbard AJ, Jones AS, Walker RT. *Nucl Acids Res.* 1984; 12:6827–37. [PubMed: 6483621]
- (xvii). Sakamoto S, Tamura T, Furukawa T, Komatsu Y, Ohtsuka E, Kitamura M, Inoue H. *Nucl Acids Res.* 2003; 31:1416–1425. [PubMed: 12595549]
- (xviii). (a) Kalman T, Nie Z, Kamat A. *Nucleosides, Nucleotides Nucleic Acids.* 2001; 20:869. [PubMed: 11563134] (b) Kalman TI, Nie Z, Kamat A. *Bioorg Med Chem Lett.* 2000; 10:391–394. [PubMed: 10714507] (c) Kalman TI, Nie Z. *Nucleosides, Nucleotides Nucleic Acids.* 2000; 19:357–369. [PubMed: 10772720]
- (xix). Bergstrom DE, Ruth JL, Reddy PA, De Clercq E. *J Med Chem.* 1984; 27:279–84. [PubMed: 6321735]
- (xx). For detailed synthesis of materials depicted in Scheme 1 please see Supporting Information.
- (xxi). (a) Rappoport, Z.; Marek, I., et al., editors. *The Chemistry of Organozinc Compounds*, Parts 1–2. John Wiley & Sons; Chichester, UK: 2006. (b) Erdik, E., editor. *Organozinc Reagents in Organic Synthesis.* CRC-Press; Boca Raton, USA: 1996. (c) Negishi, E-i; Hu, Q.; Huang, Z.; Qian, M.; Wang, G. *Aldrichimica Acta.* 2005; 38:71–88.(d) Knochel, P.; Jones, P., editors. *Organozinc Reagents: A Practical Approach.* Oxford University Press; Oxford: 1999.
- (xxii). (a) Huo S. *Org Lett.* 2003; 5:423–5. [PubMed: 12583734] (b) Jubert C, Knochel P. *J Org Chem.* 1992; 57:5425–31.(c) Krasovskiy A, Malakhov V, Gavryushin A, Knochel P. *Angew Chem, Int Ed.* 2006; 45:6040–6044.
- (xxiii). Jiang B, Xu Y. *Tetrahedron Lett.* 1992; 33:511–14.
- (xxiv). (a) Prasad ASB, Knochel P. *Tetrahedron.* 1997; 53:16711–16720.(c) Stevenson TM, Prasad ASB, Citineni JR, Knochel P. *Tetrahedron Lett.* 1996; 37:8375–8378.
- (xxv). Efforts were made to prepare the fluoroalkylzinc bromides using commercial Rieke zinc.® Even in large excess, the active zinc suspension in THF (Aldrich) was not able to convert the fluoroalkyl bromide to the corresponding zinc reagent.
- (xxvi). Concentration of fluoroalkylzinc bromide was determined by titration of an aliquot with iodine. For further detail: Krasovskiy A, Knochel P. *Synthesis.* 2006:890–891.
- (xxvii). Reactions were monitored by RP-HPLC at 268 nm and products isolated where indicated. Details outlined in supplemental information.
- (xxviii). (a) Hayashi T, Konishi M, Kobori Y, Kumada M, Higuchi T, Hirotsu K. *J Am Chem Soc.* 1984; 106:158–63.(b) Weichert A, Bauer M, Wirsig P. *Synlett.* 1996:473–474.
- (xxix). (a) Hadei N, Kantchev EAB, O'Brien CJ, Organ MG. *Org Lett.* 2005; 7:3805–3807. [PubMed: 16092880] (b) Kantchev EAB, O'Brien CJ, Organ MG. *Aldrichimica Acta.* 2006; 39:97–111.
- (xxx). Dai C, Fu GC. *J Am Chem Soc.* 2001; 123:2719–2724. [PubMed: 11456957]
- (xxxi). (a) Vittorio F. *Adv Synth Catal.* 2004; 346:1553–1582.(b) Hartwig JF, Richards S, Baranano D, Paul F. *J Am Chem Soc.* 1996; 118:3626–3633.
- (xxxii). (a) Milne JE, Buchwald SL. *J Am Chem Soc.* 2004; 126:13028–13032. [PubMed: 15469301] (b) Shen Q, Shekhar S, Stambuli JP, Hartwig JF. *Angew Chem.* 2005; 117:1395–1399.
- (xxxiii). (a) Tomori H, Fox JM, Buchwald SL. *J Org Chem.* 2000; 65:5334–5341. [PubMed: 10993363] (b) Wolfe JP, Buchwald SL. *Angew Chem, Int Ed.* 1999; 38:2413–2416.(c) Rieth RD, Mankad NP, Calimano E, Sadighi JP. *Org Lett.* 2004; 6:3981–3983. [PubMed: 15496079]
- (xxxiv). (a) Hansen AL, Ebran JP, Gogsig TM, Skrydstrup T. *J Org Chem.* 2007; 72:6464–6472. [PubMed: 17630802] (b) Shen Q, Shekhar S, Stambuli JP, Hartwig JF. *Angew Chem.* 2005;

117:1395–1399.(c) Togni A, Breutel C, Schnyder A, Spindler F, Landert H, Tijani A. *J Am Chem Soc.* 1994; 116:4062–4066.

(xxxv). Maximal yields of (3-fluoropropyl)zinc iodide were only modest as compared to our previous examples, and were obtained when the reactions were performed at 60 °C for 45 minutes.

Heating for longer led to loss of activity of zinc reagent (as determined by iodine titration).

(xxxvi). (a) Casares JA, Espinet P, Fuentes B, Salas G. *J Am Chem Soc.* 2007; 129:3508–3509. [PubMed: 17328551] (b) Gong LZ, Knochel P. *Synlett.* 2005:267–270.

(xxxvii). Prusoff WH. *Biochim Biophys Acta.* 1959; 32:295–6. [PubMed: 13628760]

(xxxviii). For preparation of dialkylzinc reagents: Cote A, Charette AB. *J Am Chem Soc.* 2008 and all references therein.

(xxxix). (a) Balatoni J, Doubrovin M, Ageyeva L, Pillarsetty N, Finn R, Gelovani J, Blasberg R. *Nucl Med Biol.* 2005; 32:811–9. [PubMed: 16253805] (b) Toyohara J, Hayashi A, Gogami A, Hamada M, Hamashima Y, Katoh T, Node M, Fujibayashi Y. *Nucl Med Biol.* 2006; 33:751–64. [PubMed: 16934694] (c) Toyohara J, Hayashi A, Gogami A, Fujibayashi Y. *Nucl Med Biol.* 2006; 33:765–772. [PubMed: 16934695]

FIGURE 1.

Structure of 5-[¹⁸F]Fluoroalkyl Nucleosides as Molecular Imaging Agents for HSV1-*tk* Gene Therapy

SCHEME 1.

Synthesis of 5-(3-Fluoropropyl) Pyrimidine Nucleoside 5a via Sonogashira Coupling Approach

SCHEME 2.

Synthesis of 5-Fluoroalkylated Pyrimidine Nucleosides 5a–f Using Saturated Fluoroalkylzincates

SCHEME 3.
 Synthesis of 5-[^{18}F]Fluoroalkylated Pyrimidine Nucleosides [^{18}F]1a–f

TABLE 1

Effect of catalyst on the Negishi coupling of (4-fluorobutyl)zinc bromide with 2a

Entry	Catalytic System	Yield ^a (%)		
		5c	8	2a
1	Pd(PPh ₃) ₄ (5 mol %)	2	3	95
2	Cl ₂ Ni(PPh ₃) ₂ (5 mol %)	0	23	77
3	Pd(dppf)Cl ₂ (5 mol %); CuI (6 mol %)	1	30	69
4	PEPPSI-IPr (5 mol %); LiBr (2 equiv.)	1	9	90
5	Pd(P(<i>t</i> -Bu) ₃) ₂ (5 mol %)	47 ^b	31	12
6	Pd(dba) ₂ (0.1 mol %); S-Phos (0.2 mol %)	5	10	85
7	Pd ₂ dba ₃ (0.1 mol %); JohnPhos (0.2 mol %)	4	10	86
8	Pd ₂ dba ₃ (0.1 mol %); PCy ₂ -JohnPhos (0.2 mol %)	0	2	98
9	Pd ₂ dba ₃ (0.1 mol %); (R,S)-JosiPhos (0.2 mol %)	0	4	96

^aHPLC yield;^bIsolated yield: 43%.

TABLE 2

Optimization of Negishi cross-coupling reaction using Pd(P(*t*-Bu)₃)₂ under various conditions

$$2a \xrightarrow[\text{DMA, rt}]{\left[\text{BrZn} \begin{array}{c} \diagup \diagdown \\ \diagdown \diagup \end{array} \begin{array}{c} \diagup \diagdown \\ \diagdown \diagup \end{array} \text{F} \right] \text{ 5 mol \% Pd(P}(t\text{-Bu)}_3)_2} 5c + 8 + 2a$$

Entry	Equiv Zn	Reagent	Time	Yield ^a (%)		
				5c ^b	8	2a
1	1.6		15 min	40	25	35
2	1.6		30 min	48	31	30
3	1.6		45 min	47	32	13
4	1.6		1 h	47 (43)	31	12
5	3		15 min	43	21	36
6	3		30 min	56 (53)	40	4
7	3		45 min	55	32	7
8	3		1 h	57 (43)	36	6
9	5		15 min	34	23	38
10	5		30 min	52 (48)	33	5
11	5		45 min	56	36	7
12	5		1 h	50 (44)	32	5
13	8		1 h	65 (26)	28	4

^a HPLC yield;

^b Values in parentheses represent isolated yield.

TABLE 3

Preparation of Library of 5-Alkylated Nucleosides by Pd(P(*t*-Bu)₃)₂-Catalyzed Negishi Cross-Coupling of Nucleoside 2a or 2b with Zincated Alkyl Halides (R'Zn-Halide)^a

Entry	Nucleoside Substrate	Zincate ^a (R' Zn-Halide)	Nucleoside Product	Product Yield ^b (%)
1	2a		5a' (X = H; R' = (CH ₂) ₃ F)	Not obtained ^c
2	2a		5a' (X = H; R' = (CH ₂) ₃ F)	8
3	2b		5b (X = F; R' = (CH ₂) ₃ F)	5
4	2a		5c (X = H; R' = (CH ₂) ₄ F)	53
5	2b		5d (X = F; R' = (CH ₂) ₄ F)	43
6	2a		5e (X = H; R' = (CH ₂) ₅ F)	50
7	2b		5f (X = F; R' = (CH ₂) ₅ F)	53
8	2a		(X = H; R' = (CH ₂) ₂ F)	Not obtained ^c
9	2a		5g (X = H; R' = Bu)	15
10	2a		5h' (X = H; R' = Pr)	17
11	2a		5i (X = H; R' = Et)	23
12	2a		5g' (X = H; R' = Bu)	44
13	2a		5i' (X = H; R' = Et)	23
14	2a		5j (X = H; R' = (CH ₂) ₅ OCOCH ₃)	33

Entry	Nucleoside Substrate	Zincate ^a ($\text{R}'\text{Zn-Halide}$)	Nucleoside Product	Product Yield ^b (%)
15	2a		5k (X = H ; $\text{R}' = (\text{CH}_2)_3\text{COOEt}$)	39
16	2a		5l (X = H ; $\text{R}' = (\text{CH}_2)_3\text{CN}$)	29
17	2a		5m (X = H ; $\text{R}' = (\text{CH}_2)_3\text{OTBS}$)	30

^aZinc reagents were prepared following Huo method;^{22a} Iodoalkylzinc reagents employed for entries 2, 3, 9–11; Commercial dialkylzinc reagents (3 equiv) employed for entries 12 and 13.

^bIsolated yields based on nucleoside substrate **2a/2b**.

^cBromoalkylzinc reagents could not be prepared following the Huo method,^{22a} thus coupling to **2a** or **2b** was not performed.